There were 2,429 press releases posted in the last 24 hours and 441,514 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image